Investment and Company Research
Opportunity Research
MICRO CAP HOT TOPICS
 

September 25, 2013

Nuvilex: The Quintessential Mid-Late Stage Biotech Opportunity

For investors seeking a well-positioned mid-late stage biotechnology company, one may not need to go any further than Nuvilex, Inc. (OTCQB – NVLX - $0.135 – Spec Buy).  The Company has nearly all of the characteristics biotech and micro cap investors find attractive and actively seek. 

Savvy biotech investors typically engage a checklist of sorts in order to ascertain a given biotech’s standing and worthiness (and occasionally valuation).  These attributes include intellectual property ownership, clinical trial development and completion, trial performance results as compared with competing firms, size of targeted treatment market, mechanism of action of drug or biologics, applicability of approach for other treatment categories, management, third party/strategic partner funding history, and upcoming milestones.

Based on the list above it is clear that Nuvilex stands perched near the top of the mid-late stage biotech standings.

The Company owns exclusive rights to a ground-breaking targeted drug delivery system that may be used to develop treatments for many different types of cancer.  The cancer treatment incorporates live, encapsulated, cancer-prodrug-activating cells implanted intravenously at the tumor site together with well-known anticancer prodrugs.  The treatment used in highly successful Phase II clinical trials in inoperable pancreatic cancer consisted of encapsulated cells plus the anticancer prodrug ifosfamide.  Results such as median survival time and one-year survival rate were significantly better in those Nuvilex predecessor trials than those reported for the 3 approved pancreatic cancer treatments, Gemzar (gemcitabine) in 1996, the combination of gemcitabine with Tarceva (erlotinib) in 2005, and the combination of gemcitabine with Abraxane (albumin-bound paclitaxel) in 2013, in their Phase 3 trials.  Moreover, the striking results in the Nuvilex trials were achieved using low chemotherapy doses, which markedly reduced the side effects from the cancer drug.

The pancreatic cancer treatment market alone is in excess of $1B and given the potential to use the therapy to treat other cancers, Nuvilex is a pure-play cancer treatment stock. Plus, there are indications that the live-cell encapsulation technology can be used to treat diabetes. To that end, the Company is nearing closure of a deal to secure the technology for diabetes as well, substantially increasing the size of the market opportunity for the Company. Clearly, Nuvilex is no one-trick pony.

Management has a wealth of experience in bringing drugs through the clinical trials and FDA process and is currently focused on the steps necessary to obtain the required number of prodrug-activating cells that will be needed prior to the initiation a Phase III clinical trial in advanced, inoperable pancreatic cancer patients.  Other milestone events prior to trial initiation include the encapsulation of the prodrug-activating cells in a GMP (Good Manufacturing Practices)-compliant facility, and the design of the clinical protocol itself.  Such milestones are critical to the Company’s development and a measure of future prospects and valuation.

At the current stage, investors can place a check mark next to all of the boxes with the exception of a strategic partner. However, strategic partnerships usually are accompanied by the commencement or conclusion of major developmental events. As a result, a third-party investment/partnership with the likes of oncology-focused firms such as Celgene (NASDAQ – CELG), Merck (NYSE – MRK), Bristol-Myers Squibb (NYSE – BMY), and others is clearly in the cards, which makes Nuvilex’s shares that much more attractive, ahead of such an event that typically drives stocks and valuations substantially higher.

For more information, refer to our previous sponsored NVLX Reports, Updates and Hot Topics by visiting www.GoldmanResearch.com

Senior Analyst: Robert Goldman
Rob Goldman has over 20 years of investment and company research experience as a senior research analyst and as a portfolio and mutual fund manager. During his tenure as a sell side analyst, Rob was a senior member of Piper Jaffray's Technology and Communications teams. Prior to joining Piper, Rob led Josephthal & Co.'s Washington-based Emerging Growth Research Group. In addition to his sell-side experience Rob served as Chief Investment Officer of a boutique investment management firm and Blue and White Investment Management, where he managed Small Cap Growth portfolios and The Blue and White Fund.

Analyst Certification
I, Robert Goldman, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report.

Disclaimer
This Opportunity Research Hot Topics article was prepared for informational purposes only. Goldman Small Cap Research, (a division of Two Triangle Consulting Group, LLC) produces research via two formats: Goldman Select Research and Goldman Opportunity Research. The Select product reflects the Firm’s internally generated stock ideas while the Opportunity product reflects sponsored research reports. It is important to note that while we may track performance separately, we utilize the same coverage criteria in determining coverage of all stocks in both research formats. While stocks in the Opportunity format may have a higher risk profile, they typically offer greater upside as well. Since April 2012, Goldman Small Cap Research has been compensated $500 per article by a third party.  This article is the opinion of Goldman Small Cap Research and was written based upon publicly available information.  The Company has not endorsed or compensated Goldman Small Cap Research for this article. All information contained in these articles was derived from GSCR due diligence. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.

Goldman Small Cap Research is not affiliated in any way with Goldman Sachs & Co.

The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research report, update, article, or note is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.

This publication does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority.

ALL INFORMATION IN THIS REPORT IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.

For more information, visit our Disclaimer: www.goldmanresearch.com